Literature DB >> 2649426

Immunocytochemical diagnosis of early myocardial ischaemic/hypoxic damage.

S Leadbeatter1, H M Wawman, B Jasani.   

Abstract

The sensitive and reliable dinitrophenyl (DNP) hapten sandwich staining (DHSS) procedure (B. Jasani et al., Virchows Arch (Pathol. Anat.), 406 (1985) 441-448) was used to study the distribution of immunoperoxidase staining seen with antibodies to seven protein markers in post-mortem heart tissue. This was obtained from 12 cases with macroscopic myocardial infarction and 17 cases without myocardial infarction (10 with and 7 without significant coronary artery atherosclerosis). The immunostaining patterns were compared with the appearances seen in adjacent sections stained by the routine haematoxylin and eosin (H & E) and phosphotungstic acid haematoxylin (PTAH) methods and a method previously recommended for the detection of early myocardial infarction, the haematoxylin basic fuchsin picric acid (HBFP) stain. Loss of immunostaining with an antibody to myoglobin was found to be a reliable and more objective marker of both early and established myocardial infarction compared with the histological stains. Antibodies to myosin, caeruloplasmin, C-reactive protein and pre-albumin gave similar but less reliable results, whilst those to complement factor C3b and alpha-1 anti-trypsin gave the least reliable results for early myocardial ischaemic/hypoxic damage. The immunocytochemical results are considered sufficiently encouraging to extend the work to a large number of sudden death cases in order to establish a new, more reliable approach to the detection of histologically latent ischaemic/hypoxic damage in the myocardium.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649426     DOI: 10.1016/0379-0738(89)90144-8

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  8 in total

1.  Early markers for myocardial ischemia and sudden cardiac death.

Authors:  Sara Sabatasso; Patrice Mangin; Tony Fracasso; Milena Moretti; Mylène Docquier; Valentin Djonov
Journal:  Int J Legal Med       Date:  2016-07-08       Impact factor: 2.686

2.  Immunohistochemical investigations to demonstrate vital direct traumatic damage of skeletal muscle.

Authors:  G Fechner; R Hauser; M A Sepulchre; B Brinkmann
Journal:  Int J Legal Med       Date:  1991       Impact factor: 2.686

3.  Technical note: EnVision™ FLEX improves the detectability of depletions of myoglobin and troponin T in forensic cases of myocardial ischemia/infarction.

Authors:  Sara Sabatasso; Catia Pomponio; Tony Fracasso
Journal:  Int J Legal Med       Date:  2017-03-23       Impact factor: 2.686

4.  Early markers of myocardial ischemia: from the experimental model to forensic pathology cases of sudden cardiac death.

Authors:  Sara Sabatasso; Milena Moretti; Patrice Mangin; Tony Fracasso
Journal:  Int J Legal Med       Date:  2017-05-11       Impact factor: 2.686

5.  Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?

Authors:  Mustafa Talip Sener; Emre Karakus; Zekai Halici; Erol Akpinar; Atilla Topcu; Ahmet Nezih Kok
Journal:  Forensic Sci Med Pathol       Date:  2014-06-18       Impact factor: 2.007

6.  The application of selected histochemical and immunohistochemical markers and procedures to the diagnosis of early myocardial damage.

Authors:  B Brinkmann; M A Sepulchre; G Fechner
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

7.  Immunohistochemical detection of early myocardial infarction. An evaluation of antibodies against the terminal complement complex (C5b-9).

Authors:  E Edston; K Kawa
Journal:  Int J Legal Med       Date:  1995       Impact factor: 2.686

8.  Forensic significance of intracardiac heme oxygenase-1 expression in acute myocardial ischemia.

Authors:  Yumi Kuninaka; Yuko Ishida; Mizuho Nosaka; Akiko Ishigami; Akira Taruya; Emi Shimada; Akihiko Kimura; Hiroki Yamamoto; Mitsunori Ozaki; Fukumi Furukawa; Toshikazu Kondo
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.